These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23517011)

  • 1. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
    Hewings DS; Fedorov O; Filippakopoulos P; Martin S; Picaud S; Tumber A; Wells C; Olcina MM; Freeman K; Gill A; Ritchie AJ; Sheppard DW; Russell AJ; Hammond EM; Knapp S; Brennan PE; Conway SJ
    J Med Chem; 2013 Apr; 56(8):3217-27. PubMed ID: 23517011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
    Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
    J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biased multicomponent reactions to develop novel bromodomain inhibitors.
    McKeown MR; Shaw DL; Fu H; Liu S; Xu X; Marineau JJ; Huang Y; Zhang X; Buckley DL; Kadam A; Zhang Z; Blacklow SC; Qi J; Zhang W; Bradner JE
    J Med Chem; 2014 Nov; 57(21):9019-27. PubMed ID: 25314271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
    Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
    ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
    Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
    Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
    J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.
    Yoo M; Park TH; Yoo M; Kim Y; Lee JY; Lee KM; Ryu SE; Lee BI; Jung KY; Park CH
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33802888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
    Jennings LE; Schiedel M; Hewings DS; Picaud S; Laurin CMC; Bruno PA; Bluck JP; Scorah AR; See L; Reynolds JK; Moroglu M; Mistry IN; Hicks A; Guzanov P; Clayton J; Evans CNG; Stazi G; Biggin PC; Mapp AK; Hammond EM; Humphreys PG; Filippakopoulos P; Conway SJ
    Bioorg Med Chem; 2018 Jul; 26(11):2937-2957. PubMed ID: 29776834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors.
    Rong J; Feng ZZ; Shi YJ; Ren J; Xu Y; Wang NY; Xue Q; Liu KL; Zhou SY; Wei W; Yu LT
    Bioorg Med Chem Lett; 2019 Oct; 29(19):126577. PubMed ID: 31421967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
    Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
    J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
    Sperandio D; Aktoudianakis V; Babaoglu K; Chen X; Elbel K; Chin G; Corkey B; Du J; Jiang B; Kobayashi T; Mackman R; Martinez R; Yang H; Zablocki J; Kusam S; Jordan K; Webb H; Bates JG; Lad L; Mish M; Niedziela-Majka A; Metobo S; Sapre A; Hung M; Jin D; Fung W; Kan E; Eisenberg G; Larson N; Newby ZER; Lansdon E; Tay C; Neve RM; Shevick SL; Breckenridge DG
    Bioorg Med Chem; 2019 Feb; 27(3):457-469. PubMed ID: 30606676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural variation of protein-ligand complexes of the first bromodomain of BRD4.
    Guest EE; Pickett SD; Hirst JD
    Org Biomol Chem; 2021 Jun; 19(25):5632-5641. PubMed ID: 34105560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
    Fedorov O; Lingard H; Wells C; Monteiro OP; Picaud S; Keates T; Yapp C; Philpott M; Martin SJ; Felletar I; Marsden BD; Filippakopoulos P; Müller S; Knapp S; Brennan PE
    J Med Chem; 2014 Jan; 57(2):462-76. PubMed ID: 24313754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Dimethylisoxazole-Attached Imidazo[1,2-
    Muthengi A; Wimalasena VK; Yosief HO; Bikowitz MJ; Sigua LH; Wang T; Li D; Gaieb Z; Dhawan G; Liu S; Erickson J; Amaro RE; Schönbrunn E; Qi J; Zhang W
    J Med Chem; 2021 May; 64(9):5787-5801. PubMed ID: 33872011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and lead identification of quinazoline-based BRD4 inhibitors.
    Yang SM; Urban DJ; Yoshioka M; Strovel JW; Fletcher S; Wang AQ; Xu X; Shah P; Hu X; Hall MD; Jadhav A; Maloney DJ
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3483-3488. PubMed ID: 30268702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.
    Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X
    J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.